Hope Bancorp, Inc. (HOPE) Shareholder/Analyst Call Prepared Remarks Transcript
Hope Bancorp, Inc. (HOPE) Shareholder/Analyst Call Prepared Remarks Transcript
Hope Bancorp, Inc. (HOPE) Q1 2026 Earnings Call Transcript
Hope Bancorp, Inc. (HOPE) Q1 2026 Earnings Call Transcript
Hope Bancorp (HOPE) Q1 Earnings Surpass Estimates
Hope Bancorp (HOPE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
Here's Why Hope Bancorp (HOPE) is a Great Momentum Stock to Buy
Does Hope Bancorp (HOPE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Capricor Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of the HOPE-3 clinical study report for Deramiocel in DMD cardiomyopathy. The FDA lifted the Complete Response Letter and set a PDUFA date of August 22, 2026, without requiring new studies, increasing regulatory clarity. Phase 3 HOPE-3 data showed Deramiocel slowed disease progression by 54% [PUL] and 91% [LVEF], with additional functional and fibrosis benefits.
Hope Bancorp, Inc. (HOPE) Q4 2025 Earnings Call Transcript
Hope Bancorp, Inc. (HOPE) Q4 2025 Earnings Call Transcript
Hope Bancorp (HOPE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Hope Bancorp (HOPE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hope Bancorp (HOPE) Q4 Earnings and Revenues Beat Estimates
Hope Bancorp (HOPE) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.2 per share a year ago.
Hope Bancorp (HOPE) Surges 5.5%: Is This an Indication of Further Gains?
Hope Bancorp (HOPE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel
Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval criteria.
Hope Bancorp, Inc. (HOPE) Q3 2025 Earnings Call Transcript
Hope Bancorp, Inc. (NASDAQ:HOPE ) Q3 2025 Earnings Call October 28, 2025 12:30 PM EDT Company Participants Maxime Olivan Kevin Kim - Chairman, President & CEO Julianna Balicka - Executive VP & CFO Peter Koh - Senior EVP & COO Conference Call Participants Matthew Clark - Piper Sandler & Co., Research Division Gary Tenner - D.A. Davidson & Co., Research Division Kelly Motta - Keefe, Bruyette, & Woods, Inc., Research Division Timothy Coffey - Janney Montgomery Scott LLC, Research Division Presentation Operator Good day, and welcome to the Hope Bancorp 2025 Third Quarter Earnings Conference Call.
Hope Bancorp (HOPE) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Hope Bancorp (HOPE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
